Use and Safety of Remdesivir in Kidney Transplant Recipients With COVID-19

Introduction: Remdesivir has demonstrated antiviral activity against coronavirus, shortening the time to recovery in adults hospitalized with moderate/severe COVID-19. Severe adverse events such as acute kidney injury have been reported. Scant data are available on the use and safety of remdesivir i...

Descripción completa

Detalles Bibliográficos
Autores: Buxeda, Anna, Arias-Cabrales, Carlos, Perez-Saez, Maria Jose, Cacho, Judit, Cabello Pelegrin, Sheila, Melilli, Edoardo, Aladren, Maria Jose, Galeano, Cristina, Lorenzo, Inmaculada, Mazuecos, Auxiliadora, Saura, Isabel Maria, Franco, Antonio, Ruiz-Fuentes, Maria del Carmen, Sanchez-Camara, Luis Alberto, Siverio, Orlando, Martin, Maria Luisa, Gonzalez-Garcia, Elena, Lopez, Veronica, Martin-Moreno, Paloma Leticia, Moina, Inigo, Moral Berrio, Esperanza, Moreso, Francesc, Portoles, Jose Maria, Santana-Estupinan, Raquel, Zarraga, Sofia, Canal, Cristina, Sanchez-Alvarez, Emilio, Pascual, Julio, Crespo, Marta, Spanish Soc Nephrology COVID-19 Gr
Tipo de recurso: artículo
Fecha de publicación:2021
País:España
Institución:Conselleria de Salut i Consum del Govern de les Illes Balears
Repositorio:Docusalut
Idioma:inglés
OAI Identifier:oai:docusalut.com:20.500.13003/19889
Acceso en línea:https://hdl.handle.net/20.500.13003/19889
Access Level:acceso abierto
Palabra clave:acute kidney injury
immunosuppression
kidney transplantation
remdesivir
SARS-CoV2l
Descripción
Sumario:Introduction: Remdesivir has demonstrated antiviral activity against coronavirus, shortening the time to recovery in adults hospitalized with moderate/severe COVID-19. Severe adverse events such as acute kidney injury have been reported. Scant data are available on the use and safety of remdesivir in kidney transplant recipients. Methods: We present a multicenter cohort study of 51 kidney transplant recipients with COVID-19 treated with remdesivir. Outcomes and safety were assessed. Results: Mean age at diagnosis was 60 years, with a median time since kidney transplant of 4.5 years. Mean time since admission to remdesivir was 2 days. Twenty-eight patients (54.9%) required mechanical ventilation (19 noninvasive). Mortality was 18.9% and markedly higher if aged >= 65 years (45% vs. 3.2% in younger patients). Acute kidney injury was present in 27.7% of patients, but was diagnosed in 50% before treatment. No patients required remdesivir discontinuation because of adverse events. We did not find significant hepatoxicity or systemic symptoms resulting from the drug. Conclusion: In our cohort of kidney transplant recipients, remdesivir was well tolerated and safe in renal and hepatic toxicity, but randomized trials are needed to assess its efficacy.

Similares en LA Referencia